Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

A case report of ruxolitinib reversing myelofibrosis

View Full Paper
Ask AI
Bookmark
Share

Authors

YYYunfang YangTNTing NiuLPLing Pan

Discussion

Loading...

Member takes

Overview

Case report demonstrates reversal of myelofibrosis and symptom improvement in a patient using ruxolitinib treatment.

Key Points

  • To report the successful treatment of a patient with Primary Myelofibrosis using ruxolitinib and its impact on symptoms and disease status.
  • Detailed case report of patient with Primary Myelofibrosis
  • Sequential treatments included hydroxyurea and interferon prior to ruxolitinib initiation
  • Ruxolitinib was administered at 15 mg twice daily for over 15 months
  • Patient experienced significant improvement in symptoms including abdominal pain and night sweats
  • MPN-10 score decreased from 46 points to 17 points after 15 months of ruxolitinib
  • Reversal of myelofibrosis achieved, reducing from MF-3 to MF-1

Cite This Study

Yang et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e2c3https://doi.org/10.1182/blood-2025-6480
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Significant improvement of bone marrow fibrosis in patients with chronic myeloproliferative neoplasms (CMPN) treated with ruxolitinib.2025
  2. 2Clinical and hematological factors predicting the effectiveness of ruxolitinib in primary and secondary myelofibrosis. Results of a prospective single-center study2024 · 1 citations
  3. 3Efficacy and safety of ruxolitinib in patients with lower risk myelofibrosis: A single-arm, exploratory and prospective study.2024
  4. 4Ten-year journey with myelofibrosis: real-world data and clinical outcomes from a tertiary care center2025
  5. 5Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls2012 · 218 citations